Ignite Creation Date:
2025-12-26 @ 11:08 AM
Ignite Modification Date:
2025-12-29 @ 8:14 AM
Study NCT ID:
NCT05017012
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-12-27
First Post:
2021-08-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-09-21
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09-26
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-09-26
Completion Date Type:
ESTIMATED
First Submit Date:
2021-08-18
First Submit QC Date:
None
Study First Post Date:
2021-08-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-24
Last Update Post Date:
2024-12-27
Last Update Post Date Type:
ACTUAL